|
Volumn 65, Issue 1, 2006, Pages 133-
|
Inadequate growth hormone (GH) suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' GH levels [2]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
GROWTH HORMONE;
OCTREOTIDE;
ACROMEGALY;
CHRONIC DRUG ADMINISTRATION;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG INDICATION;
HORMONE RESPONSE;
HUMAN;
LETTER;
PATIENT SELECTION;
PRIORITY JOURNAL;
REMISSION;
SAFETY;
TREATMENT RESPONSE;
ACROMEGALY;
CHEMOTHERAPY, ADJUVANT;
DELAYED-ACTION PREPARATIONS;
GROWTH HORMONE;
HUMANS;
OCTREOTIDE;
SOMATOSTATIN;
|
EID: 33745208428
PISSN: 03000664
EISSN: 13652265
Source Type: Journal
DOI: 10.1111/j.1365-2265.2006.02549.x Document Type: Letter |
Times cited : (1)
|
References (4)
|